1. Home
  2. ETSY vs DFTX Comparison

ETSY vs DFTX Comparison

Compare ETSY & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Etsy Inc.

ETSY

Etsy Inc.

N/A

Current Price

$76.26

Market Cap

6.9B

ML Signal

N/A

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$37.25

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ETSY
DFTX
Founded
2005
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
5.9B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
ETSY
DFTX
Price
$76.26
$37.25
Analyst Decision
Buy
Strong Buy
Analyst Count
30
18
Target Price
★ $88.33
$71.65
AVG Volume (30 Days)
★ 2.8M
2.3M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.25
N/A
Revenue
★ $441,231,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.72
N/A
P/E Ratio
$300.56
★ N/A
Revenue Growth
★ 20.90
N/A
52 Week Low
$44.00
$14.62
52 Week High
$87.97
$49.70

Technical Indicators

Market Signals
Indicator
ETSY
DFTX
Relative Strength Index (RSI) 57.04 48.36
Support Level $71.38 $36.11
Resistance Level $87.13 $44.60
Average True Range (ATR) 3.01 1.87
MACD 0.82 -0.04
Stochastic Oscillator 97.36 61.85

Price Performance

Historical Comparison
ETSY
DFTX

About ETSY Etsy Inc.

Founded in 2005, Etsy operates a leading global marketplace, connecting roughly 87 million active buyers and 6 million sellers of unique, handmade, and vintage goods. In fiscal 2025, the firm generated $2.9 billion in revenue and almost $12 billion in gross merchandise sales. The firm monetizes its marketplace primarily through transaction fees and advertising, with core categories spanning homeware, jewelry, apparel, and craft supplies. The US drives 74% of sales, though its core geographic reach extends to the UK, Germany, Canada, and Australia.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: